H. Bojar

H. Bojar, M. Basler, C. Broelsch, 1976, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

Quality control requirements in estrogen receptor determination.

H. Bojar, 1986, Cancer research.

Grading system for breast cancer.

A. Schauer, M. Schumacher, H. Bojar, 1998, Anticancer research.

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2

H. Bojar, T. Bakács, A. Szász, 2018, Integrative cancer therapies.

Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma.

H. Bojar, H. Merk, A. Baltzer, 2002, Anticancer research.

Heart ß-Receptors: On the Functional Role of Heterogeneous Binding Sites

H. Bojar, A. Kaumann, T. H. Morris, 1983 .

Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells.

H. Bojar, U. Steidl, U. Rohr, 2002, Blood.

The synthetic androgen mibolerone induces transient suppression of the transformed phenotype in an androgen responsive human prostatic carcinoma cell line: Das synthetische Androgen Miboleron induziert eine transiente Suppression des transformierten Phänotyps in einer Androgen‐abhängigen menschliche

H. Bojar, D. Wolf, V. Arbusow, 1990, Andrologia.

Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures

H. Bojar, H. Prisack, O. Modlich, 2005, Journal of Translational Medicine.

Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution

H. Bojar, A. Baierl, T. Bakács, 2020, Cancer Immunology, Immunotherapy.

Dual-Parameter Immunoflow Cytometry in Diagnosis and Follow-Up of Patients with Bladder Cancer

H. Bojar, T. Ebert, B. Schmitz-Dräger, 1998, European Urology.

Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients

H. Bojar, G. Steinbach, A. Erhardt, 2011, European journal of medical research.

Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node‐positive breast‐cancer patients

W. Sauerbrei, M. Schumacher, G. Bastert, 2000, International journal of cancer.

Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome

H. Bojar, W. Schulz, M. Grimm, 2007, Cancer.

A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

L. Holmberg, J. Rahnenführer, K. Edlund, 2012, Clinical Cancer Research.

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

C. Denkert, M. Dietel, J. Budczies, 2012, British Journal of Cancer.

Effects of high-dose medroxyprogesterone acetate and various other steroid hormones on plasma membrane lipid mobility in CAMA-1 mammary cancer cells.

H. Bojar, T. Marsen, T. van Bömmel, 1987, Anticancer research.

Investigation on the thermostability of steroid hormone receptors in lyophilized calf uterine tissue powder

H. Bojar, K. Beck, W. Staib, 1980, Cancer.

The endocrine background of human renal cell carcinoma. IV. Glucocorticoid receptors as possible mediators of progestogen action.

H. Bojar, W. Staib, K. Maar, 1979, Urologia internationalis.

The endocrine background of human renal cell carcinoma. I. Binding of the highly potent progestin R 5020 by tumour cytosol.

H. Bojar, W. Staib, K. Maar, 1979, Urologia internationalis.

PROPERTIES OF SPECIFIC ESTROGEN-BINDING COMPONENTS IN HUMAN KIDNEY AND RENAL CARCINOMA

H. Bojar, J. Wittliff, K. Balzer, 1975 .

Oestrogen-Binding Components in Human Renal Cell Carcinoma

H. Bojar, J. Wittliff, K. Balzer, 1976, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

Identification and Partial Characterization of Specific Oestrogen-Binding Components in Human Kidney

H. Bojar, J. Wittliff, K. Balzer, 1976, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer

C. Denkert, M. Dietel, H. Bojar, 2014, Virchows Archiv.

Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector

H. Bojar, F. Heyd, U. Steidl, 2003, Cancer Gene Therapy.

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction

Holger Sültmann, Jan G. Hengstler, Jörg Rahnenführer, 2010, Clinical Cancer Research.

The endocrine background of human renal cell carcinoma. V. Binding of the highly potent androgen methyltrienolone (R 1881) by tumour cytosol.

H. Bojar, W. Staib, K. Maar, 1980, Urologia internationalis.

Hormone responsiveness of renal cancer

H. Bojar, 1984, World Journal of Urology.

rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid: a new option as immuno-therapy for osteosarcoma?

H. Bojar, H. Merk, A. Baltzer, 2002, Anticancer research.

E¡ects of tamoxifen on human squamous cell carcinoma lines of the head and neck

H. Bojar, V. Balz, H. Bier, 2002 .

Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease

H. Bojar, H. Prisack, O. Modlich, 2004, Clinical Cancer Research.

Modelling the effects of standard prognostic factors in node-positive breast cancer

M Schumacher, P Royston, W Sauerbrei, 1999, British Journal of Cancer.

Differentiated DNA analysis in relation to steroid receptor status, grading, and staging in human breast cancer.

H. Bojar, G. Meckenstock, W. Hort, 1987, Anticancer research.

The Estrogen Receptor Paradox in Breast Cancer: Association of High Receptor Concentrations with Reduced Overall Survival

M. Rezai, H. Bojar, W. Audretsch, 2000, The breast journal.

Tumor-Specific Immediate Reconstruction in Breast Cancer Patients

M. Rezai, H. Bojar, C. Kolotas, 1998 .

Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow – derived and circulating human CD 34 1 hematopoietic stem cells

H. Bojar, U. Steidl, U. Rohr, 2002 .

Marker in Human Solid Tumors C as a Compatible Prognostic κ Identifies Stromal Immunoglobulin A Comprehensive Analysis of Human Gene Expression Profiles

L. Holmberg, K. Edlund, H. Bojar, 2012 .

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission : results of a multivariate analysis.

H. Bojar, R. Sauer, C. Matuschek, 2013, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission

H. Bojar, R. Sauer, C. Matuschek, 2012, Strahlentherapie und Onkologie.

Radiotherapy with different fractionations and simultaneous cisplatin or carboplatin in the treatment of advanced head and neck carcinomas: clinical results and radiobiological investigations.

H. Bojar, H. Bier, C. Kolotas, 1994, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[The significance of clinical prodromes for dosage estimation after whole-body radiation exposure].

H. Bojar, N. Zamboglou, G. Schmitt, 1994, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

Detection and partial characterization of glucocorticoid-binding components in hepatic metastases of human bronchial and gastric carcinoid tumors.

H. Bojar, C. Broelsch, S. Westerkamp, 1980, Hepato-gastroenterology.

Steroid receptor status of human testicular tumors.

H. Bojar, L. Weissbach, D. Petzinna, 1985, Urologia internationalis.

Gene expression of circulating tumour cells in breast cancer patients

H. Bojar, R. Mota, C. Matuschek, 2009, European journal of medical research.

WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines.

H. Bojar, W. Schulz, B. Schmitz-Dräger, 1998, International journal of oncology.

Identification and partial characterization of glucocorticoid receptors in human liver.

H. Bojar, C. Broelsch, S. Westerkamp, 1980, Hepato-gastroenterology.

The effect of oral contraceptive use on the prognosis of node positive breast cancer patients.

W. Sauerbrei, M. Blettner, M. Schumacher, 1998 .

Retrospective Study of Neoadjuvant Versus Adjuvant Radiochemotherapy in Locally Advanced Noninflammatory Breast Cancer

H. Bojar, R. Willers, S. Roth, 2010, Strahlentherapie und Onkologie.

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. German Breast Cancer Study Group.

W. Sauerbrei, M. Schumacher, G. Bastert, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Steroid receptor pattern of human colorectal neoplasms.

H. Bojar, D. Petzinna, M. Heim, 1984, Anticancer research.

Correction to: The role of passive immunization in the age of SARS-CoV-2: an update

H. Bojar, A. Lichtenberg, D. Häussinger, 2020, European Journal of Medical Research.

Insulin effect on translational diffusion of lipids and proteins in the plasma membrane of isolated rat hepatocytes.

H. Bojar, M. Stuschke, 1985, Biochimica et biophysica acta.

Can a 70-gene signature provide useful prognostic information in patients with node-negative breast cancer?

H. Bojar, O. Modlich, Olga Modlich, 2007, Nature Clinical Practice Oncology.

[A study of the quantitative dual-parameter flow cytometry analyses of cellular antigens on transitional cells for the diagnosis of bladder cancer].

H. Bojar, T. Ebert, B. Schmitz-Dräger, 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.

W. Sauerbrei, M. Schumacher, G. Bastert, 2001, European journal of cancer.

Gene Therapy for Treatment of Brain Tumors (HSV-tKIn Vivo Gene Transfer) : A Case Study.

F. Floeth, H. Bojar, F. Weber, 2000, Methods in molecular medicine.

Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model.

H. Bojar, H. Merk, A. Baltzer, 2004, Anticancer research.

Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells.

H. Bojar, H. Merk, A. Baltzer, 2002, Cytokines, cellular & molecular therapy.

STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases.

H. Bojar, A. Tannapfel, A. Mirmohammadsadegh, 2006, The Journal of investigative dermatology.

The endocrine background of human renal cell carcinoma. III. Role of inhibitors of R 5020 binding in tumour cytosol.

H. Bojar, W. Staib, K. Maar, 1979, Urologia internationalis.

Gene expression profiles in the acutely dissected human aorta.

H. Bojar, H. Bojar, H. Prisack, 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study

H. Bojar, C. Poremba, C. Matuschek, 2014, European Journal of Medical Research.

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction

J. Rahnenführer, H. Sültmann, H. Bojar, 2010, Clinical Cancer Research.

The effect of oral contraceptive use on the prognosis of node positive breast cancer patients. German Breast Cancer Study Group.

W. Sauerbrei, M. Blettner, M. Schumacher, 1998, European journal of cancer.

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission: Results of a multivariate analysis.

H. Bojar, R. Sauer, S. Roth, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Journal of Translational Medicine Gene Expression in Acute Stanford Type a Dissection: a Comparative Microarray Study

H. Bojar, P. Feindt, E. Gams, 2022 .